1. Home
  2. AUGO vs GPCR Comparison

AUGO vs GPCR Comparison

Compare AUGO & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aura Minerals Inc.

AUGO

Aura Minerals Inc.

HOLD

Current Price

$84.91

Market Cap

4.8B

Sector

N/A

ML Signal

HOLD

Logo Structure Therapeutics Inc.

GPCR

Structure Therapeutics Inc.

HOLD

Current Price

$47.34

Market Cap

3.8B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
AUGO
GPCR
Founded
1946
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
4.8B
3.8B
IPO Year
2009
2023

Fundamental Metrics

Financial Performance
Metric
AUGO
GPCR
Price
$84.91
$47.34
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
12
Target Price
$67.60
$103.17
AVG Volume (30 Days)
891.3K
549.2K
Earning Date
05-06-2026
05-08-2026
Dividend Yield
1.97%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$91.05
N/A
Revenue Next Year
$17.09
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$29.11
$20.04
52 Week High
$110.32
$94.90

Technical Indicators

Market Signals
Indicator
AUGO
GPCR
Relative Strength Index (RSI) 63.59 41.03
Support Level $78.80 $46.40
Resistance Level $91.24 $56.63
Average True Range (ATR) 4.12 2.26
MACD -0.59 -0.59
Stochastic Oscillator 81.69 19.33

Price Performance

Historical Comparison
AUGO
GPCR

About AUGO Aura Minerals Inc.

Aura Minerals Inc is a mid-tier gold and copper production company focused on the development and operation of gold and base metal projects in the Americas. The company's operating segments include: Minosa Mine, Apoena Mine, the Aranzazu Mine, Almas Mine, Borborema Mine and Serra Grande Mine. It derives maximum revenue from Aranzazu Mine. The company's growth projects include: Matupa in Brazil, and Era Dorada in Guatemala. whereas its exploration projects include: Carajas, in Brazil, and Tolda Fria in Colombia.

About GPCR Structure Therapeutics Inc.

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.

Share on Social Networks: